Ultragenyx gets FDA approval for rare disease gene therapy

Ultragenyx has received official FDA approval for its new gene therapy designed to treat a rare disease. Following the announcement of this regulatory milestone, the company's stock experienced a significant positive reaction, surging by 10%. This development marks a critical achievement for Ultragenyx in the field of genetic medicine, as the FDA authorization allows the therapy to move forward toward patient availability, directly impacting the organization's market valuation and strategic growth within the biotechnology sector.